# Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)

> **NCT00248365** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kiadis Pharma** · enrollment: 20 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **BIOLOGICAL:** Theralux extracorporeal photochemotherapy

## Key facts

- **NCT ID:** NCT00248365
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248365, "Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00248365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*